This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Reply to Indexing of Reports on Aripiprazole Augmentation of Clozapine

Harpreet S. Duggal, MD, DPM, and Dattatreya N. Mendhekar, MD, DPM

Published: February 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We thank Dr. Ashton for his interest in our letter. It is encouraging to see that other psychiatrists have tried aripiprazole at higher doses and also in combination with other atypical antipsychotics in treatment-resistant schizophrenia.

While the issue of using high doses of antipsychotics and combining 2 atypicals is still debatable, we agree with Dr. Ashton that more reporting of such cases would enhance understanding of and also stimulate research in this area.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...